SYS-CON MEDIA Authors: Jason Bloomberg, Kevin Benedict, David H Deans, RealWire News Distribution, Gilad Parann-Nissany

News Feed Item

Lotus Pharmaceutical Company Inc. Filed Its Abbreviated New Drug Application (ANDA) Containing a Paragraph IV Certification for a Generic Version of Xenical(R) with the U.S. Food & Drug Administration (FDA)

TAIPEI, Taiwan, Dec. 11, 2012 /PRNewswire/ -- Lotus Pharmaceutical Company Inc. has confirmed its submission of Abbreviated New Drug Application ("ANDA") for Orlistat capsules, a generic version of Xenical®, to the US Food and Drug Administration (FDA). Lotus has informed Hoffman La Roche on the Paragraph IV certification within 20 days of its submission at the end of September, notifying them of the application and providing documents on non-infringement. So far, Roche has not filed a patent lawsuit within 45 days in accordance with current regulations.

Xenical is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet.  

About Lotus Pharmaceutical Company Inc.

Lotus Pharmaceutical Company Inc. is a Taiwan based emerging specialty pharmaceutical company dedicated to the development and manufacturing of oral solid dosage forms of generics including hormone, cytotoxic and soft-gel capsule products. It has filed several ANDA applications since 2008. Lotus is headquartered in Nantou, Taiwan. 

For more information, please contact:

Charles Lin
President of Lotus Pharmaceutical Company Inc.
[email protected] 

Marketing Manager
Peter Chen
[email protected] 
+886-2-27785188 ext 256

 

 

SOURCE Lotus Pharmaceutical Company Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.